Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patie...
المؤلفون الرئيسيون: | S Ahmad, S, Qian, W, Ellis, S, Mason, E, Khattak, M, Gupta, A, Shaw, H, Quinton, A, Kovarikova, J, Thillai, K, Rao, A, Board, R, Nobes, J, Dalgleish, A, Grumett, S, Maraveyas, A, Danson, S, Talbot, T, Harries, M, Marples, M, Plummer, R, Kumar, S, Nathan, P, Middleton, M, Larkin, J, Lorigan, P, Wheater, M, Ottensmeier, C, Corrie, P |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Lippincott, Williams and Wilkins
2015
|
مواد مشابهة
-
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
حسب: Lorigan, P, وآخرون
منشور في: (2014) -
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
حسب: Dalle, S, وآخرون
منشور في: (2021) -
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab
حسب: M. Hardy-Werbin, وآخرون
منشور في: (2018-02-01) -
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
حسب: Gupta, A, وآخرون
منشور في: (2014) -
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
حسب: Gupta, A, وآخرون
منشور في: (2013)